H.C. Wainwright lowered the firm’s price target on AnaptysBio (ANAB) to $52 from $59 and keeps a Buy rating on the shares after the Phase 2 rosnilimab trial in ulcerative colitis does not meet the primary endpoint. The firm removed ulcerative colitis revenues from its model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB: